Literature DB >> 27481110

Association of VEGF gene polymorphisms with sporadic Parkinson's disease in Chinese Han population.

Yubin Wu1, Yingying Zhang1, Xun Han2, Xiaoyuan Li1, Li Xue3, Anmu Xie4.   

Abstract

Recent evidence indicates that vascular endothelial growth factor (VEGF) is capable of protecting dopaminergic (DA) neurons. Parkinson's disease (PD) is a progressive neurodegenerative disease caused by the degeneration of nigrostriatal dopaminergic neurons. To evaluate the role of VEGF single nucleotide polymorphisms (SNPs) and haplotypes in PD, we performed a case-control study including 400 PD patients and 400 healthy-matched controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and DNA sequencing were used to detect the rs699947, rs2010963 and rs3025039 polymorphisms of the VEGF gene in cases and controls. Our study revealed that T allelic frequency of rs3025039 polymorphism was significantly higher in PD subjects (OR 1.497, 95 % CI 1.099-2.040, P = 0.013) than that in controls. Significant association for rs3025039 could be found in additive model (TT vs. CT vs. CC: OR 1.489, 95 % CI 1.018-2.177, P = 0.040) and dominant model (TT + CT vs. CC: OR 1.538, 95 % CI 1.068-2.216, P = 0.021). Subgroup analyses performed by gender suggested that this association could be found in male, but not in female. Moreover, it also demonstrated a significant association in the subgroup of late-onset PD (LOPD). However, for rs699947 and rs2010963 polymorphisms, genotype or allele frequencies did not differ between groups. No significant association could be found between rs699947 and rs2010963 polymorphism and PD risk. None of the observed haplotypes showed significant association with PD. Therefore, these results suggested that the VEGF gene might be associated with risk of developing sporadic PD in Han Chinese and the rs3025039 polymorphism may be a risk factor for sporadic PD.

Entities:  

Keywords:  Haplotypes; Parkinson’s disease (PD); Single-nucleotide polymorphisms (SNPs); Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2016        PMID: 27481110     DOI: 10.1007/s10072-016-2691-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  26 in total

1.  Lack of association between VEGF polymorphisms and ALS in a Dutch population.

Authors:  P W J Van Vught; N A Sutedja; J H Veldink; B P C Koeleman; G J Groeneveld; C Wijmenga; B M J Uitdehaag; J M B V de Jong; F Baas; J H J Wokke; L H Van den Berg
Journal:  Neurology       Date:  2005-11-22       Impact factor: 9.910

2.  Neurorescue effects of VEGF on a rat model of Parkinson's disease.

Authors:  Takao Yasuhara; Tetsuro Shingo; Kenichiro Muraoka; Masahiro Kameda; Takashi Agari; Yuan Wen Ji; Hitoshi Hayase; Hirofumi Hamada; Cesario V Borlongan; Isao Date
Journal:  Brain Res       Date:  2005-08-16       Impact factor: 3.252

3.  Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat.

Authors:  Marie-Sophie Quittet; Omar Touzani; Laurence Sindji; Jérôme Cayon; Fabien Fillesoye; Jérôme Toutain; Didier Divoux; Léna Marteau; Myriam Lecocq; Simon Roussel; Claudia N Montero-Menei; Myriam Bernaudin
Journal:  Acta Biomater       Date:  2014-12-31       Impact factor: 8.947

4.  Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease.

Authors:  Torsten Falk; Xu Yue; Shiling Zhang; Alexander D McCourt; Brandon J Yee; Robert T Gonzalez; Scott J Sherman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

5.  VEGF polymorphisms and serum VEGF levels in Parkinson's disease.

Authors:  Ebru Mihci; Sibel S Ozkaynak; Nilgun Sallakci; Ferah Kizilay; Ugur Yavuzer
Journal:  Neurosci Lett       Date:  2011-02-18       Impact factor: 3.046

6.  Parkinson disease: from pathology to molecular disease mechanisms.

Authors:  David T Dexter; Peter Jenner
Journal:  Free Radic Biol Med       Date:  2013-02-04       Impact factor: 7.376

7.  Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer.

Authors:  Joong-Seok Kim; Sung-Vin Yim; In Song Koh; Jin Soo Choi; Ji-Yeon Yoo; Kwang-Soo Lee; Young Lim; Kweon-Haeng Lee
Journal:  Arch Gerontol Geriatr       Date:  2008-03-21       Impact factor: 3.250

8.  VEGF genetic variability is associated with increased risk of developing Alzheimer's disease.

Authors:  Roberto Del Bo; Serena Ghezzi; Elio Scarpini; Nereo Bresolin; Giacomo Pietro Comi
Journal:  J Neurol Sci       Date:  2009-03-09       Impact factor: 3.181

9.  Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury.

Authors:  Janette M Krum; Nina Mani; Jeffrey M Rosenstein
Journal:  Exp Neurol       Date:  2008-04-03       Impact factor: 5.330

Review 10.  VEGF: a critical player in neurodegeneration.

Authors:  Erik Storkebaum; Peter Carmeliet
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

View more
  2 in total

1.  Association of ATG5 gene polymorphism with Parkinson's disease in a Han Chinese population.

Authors:  Jing Han; Ganghua Feng; Jibao Wu; Yi Zhang; Zhipeng Long; Xiaoxi Yao
Journal:  Acta Neurol Belg       Date:  2021-10-18       Impact factor: 2.471

2.  Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.

Authors:  Gianluca Trifirò; Ilaria Marcianò; Paola M Cutroneo; Edoardo Spina; Eliana Mirabelli; Costantino J Trombetta; Francesca Morgante
Journal:  Front Pharmacol       Date:  2018-06-08       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.